The effects of the Seven Acupoints of the Cranial Base on health related quality of life for patients with Parkinson’s disease：a randomized controlled trial
10.3760/cma.j.issn.1673-4246.2014.07.011
- VernacularTitle:针刺颅底七穴干预帕金森病患者生存质量的随机对照研究
- Author:
Xin LIANG
;
Feng CHEN
- Publication Type:Journal Article
- Keywords:
Parkinson’s disease;
Quality of life;
Acupuncture;
the Seven acupoints of the cranial base;
Parkinson's disease questionnaire-39
- From:International Journal of Traditional Chinese Medicine
2014;(7):613-616
- CountryChina
- Language:Chinese
-
Abstract:
Objectives To evaluate the effects of“the Seven Acupoints of the Cranial Base”(SACB) in improving quality of life(QOL)of patients with PD. Methods The study Subjects were seventy(70)patients with a diagnosis of Parkinson's disease. The Subjects were divided into two groups, i.e. acupuncture group and drug group.The former was treated by SACB every two days,while the latter took Levodopa and Benserazide Tablet250mg tid. The subjects all received treatment for 6 months. PDQ-39,UPDRSⅡand PDSS were adopted to measure quality of life at 4 time points. Results The total effective rate of the treatment group was 85.71%, the control group was 71.43%. And there was a statistical difference of level distribution between the two groups(P<0.01). The total score of PDQ-39, UPDRSⅡ and PDSS of patients in the treatment group [(20.41± 11.64), (9.09±5.02), (126.31±8.37)]were significantly improved compared with the control group[(27.48± 8.69), (10.29±4.93), (109.94±8.11), P<0.01]. The 5 dimension score of PDQ-39, and the 4 single item score of UPDRSⅡ in the treatment group[(8.60±5.07), (3.20±2.08), (2.34±1.73), (1.20±1.68), (1.63±1.96),(1.31±0.68), (0.77±0.94), (0.91±0.74), (0.77±0.65)]were significantly improved compared with the control group[(11.69±4.11), (5.09±3.72), (5.37±1.99), (2.86±2.33), (2.74±2.08), (1.74±0.98), (1.31±0.93), (1.43±0.78), (1.20±0.68), P<0.01 or 0.05]. Conclusion SACB can markedly and multi-dimensionally improve the QOL of patients with PD and has a higher efficacy than Levodopa and Benserazide Tablet.
